Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure

Aliment Pharmacol Ther. 2016 May;43(9):1019-20. doi: 10.1111/apt.13565.
No abstract available

Publication types

  • Letter
  • Kommentar

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Polyethylene Glycols / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols